Ivig
DefinitionThis section has been translated automatically.
Intravenous therapy with human immunoglobulins.
IndicationThis section has been translated automatically.
For the indications listed here, there are guideline recommendations with varying degrees of evidence.
- Dermatomyositis (polymyositis) Level of evidence Ib
- Severe forms of systemic lupus erythematosus
- ANCA negative vasculitis
- Severe forms of blistering autoimmune diseases (level of evidence Ib)
- Pyoderma gangraenosum
- Toxic epidermal necrolysis (TEN)
- livedo racemosa
- Livedovasculopathy
- autoimmunological urticaria
- Kawasaki Syndrome
- Casuistic articles have been published on pemphigus vulgaris, Arndt-Gottron scleromyxedema and CREST syndrome.
Dosage and method of useThis section has been translated automatically.
0,2-1,0 (up to 2,0 g) g/kg bw i.v. over several days (guideline standard dosage: 2g/kg bw over 2-5 days).
Undesirable effectsThis section has been translated automatically.
See below Immunoglobulins, non-specific.
Severe ADRs are rare. These include anphylactic reactions, aseptic meningitis, acute renal failure and thromboembolic complications. Neutropenia and mild thrombocytopenia are common but have received little attention (Stoevesand J et al. 2020).
PreparationsThis section has been translated automatically.
Intratect, Pentaglobin
LiteratureThis section has been translated automatically.
- Ahmed AR et al. (2007) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355: 1772-1779
- Hadaschik E et al. (2020) European guidelines (S1) for the use of high-dose intravenous immunoglobulins in dermatology. Dermatology 71:542-552.
- Lemm G (2002) Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 59(12 Suppl 6): S28-32
- Sami N et al. (2002) Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 105: 192-198
- Samuelsson A et al. (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486
- Simon HU, Spath PJ (2003) IVIG - mechanisms of action. Allergy 58: 543-552
- Schanz S et al. (2008) Response of dystrophic calicification to intravenous immunoglobulin. Arch Dermatol 144: 585-587
- Schwörer CV(2015) Guideline for the use of IVIG in dermatology. derm 21:233
- Topf S et al. (2007) Significant improvement of Arndt-Gottron scleromyxedema with high-dose intravenous immunoglobulins. Dermatologist 58: 525-528